Table 3: Statistical significant dates involving Hox polymorphisms.
| Groups | Polymorphism | Nucleoside | MBS patients (n = 30) | Control groups (n = 30) | p-value |
| MBS patients Versus Non-MBS patients | A315T (Hoxb1) | MBS patients (n = 30) | Non-MBS patients (n = 30) | ||
| AA | 26 (86.7) | 17 (56.7) | 0.02 | ||
| AT | 4 (13.3) | 12 (40) | |||
| TT | 0 (0) | 1 (3.3) | |||
| MBS patients Versus Non-consanguineous and Non-syndromic patients (control group 2) | C243T (Hoxb1) | MBS patients (n = 30) | Non-consanguineous and non- syndromic (n = 15) | p-value | |
| CC | 22 (73.3) | 6 (40) | 0.03 | ||
| CT | 8 (26.7) | 7 (46.7) | |||
| TT | 0 (0) | 2 (13.3) | |||
| A315T (Hoxb1) | AA | 26 (86.7) | 7 (46.6) | 0.01 | |
| AT | 4 (13.3) | 7 (46.7) | |||
| TT | 0 (0) | 1 (6.7) | |||
| G456A (Hoxb1) | GG | 20 (66.7) | 5 (33.3) | 0.02 | |
| GA | 10 (33.3) | 7 (46.7) | |||
| AA | 0 (0) | 3 (20) | |||
| MBS patients Versus Their relatives (Control group 1) | G218A (Hoxa1) | MBS patients (n = 30) | Consanguineous (n = 15) | p-value | |
| GG | 0 (0) | 1 (6.6) | 0.03 | ||
| GA | 11 (36.7) | 1 (6.7) | |||
| AA | 19 (63.3) | 13 (86.7) |